BUILDING A GLOBAL PHARMA LEADER
Impact with Long-Acting Injectables
Corporate Presentation - January 2020
© MedinCell - January 2020
IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING
The following applies to this document, the oral presentation of the information in this document by Medincell S.A. (the "Company") or any person on behalf of the Company and any question-and-answer session that follows the oral presentation (collectively, the "Information").
We remind you that you have agreed, prior to being granted access to the Information, that: (i) you will not disclose the Information to anyone within your firm (other than and subject to the restrictions you have agreed to when your firm was initially contacted) or outside your firm, and (ii) these restrictions will apply to your entire firm. By attending the meeting where this presentation is made, or by reading this document, you further agree to be bound by the following limitations and qualifications. Failure to comply with these may constitute a violation of applicable securities laws.
The Information is delivered to you on the basis of your compliance with the legal and regulatory obligations to which you are subject. Copies of this document must be returned at the end of the meeting. This document may not be removed from the premises.
If this document has been received in error, it must be immediately returned, along with any other copies, to the Company. The Information is made available on a confidential basis, to a limited number of recipients solely for the purposes of preliminary discussions regarding a potential initial public offering of the Company (the "Proposed Transaction"). The Information, including this presentation and its contents, has not been verified by Bryan Garnier or Crédit Agricole CIB (the "Banks"), or any of their affiliates, shareholders, directors, officers, advisers, employees and representatives or otherwise independently verified.
Some of the financial information contained in this document has been prepared in accordance with French GAAP. French GAAP differ from International Financial Reporting Standards (IFRS); related financial information is therefore not directly comparable. In addition, some of the financial information contained in this document is not directly extracted from the Company's accounting systems or records and is not IFRS accounting measures; it has not been independently reviewed or verified by the Company's auditors or by the Banks.
The market data and certain industry forecasts included in this document were obtained from internal surveys, estimates, reports and studies, where appropriate, as well as external market research, publicly available information and industry publications. The Company, the Banks, their affiliates, shareholders, directors, officers, advisors, employees and representatives have not independently verified the accuracy of any such market data and industry. Such data and forecasts are included herein for information purposes only.
This document contains certain statements that are forward-looking. These statements refer in particular to the Company management's business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which are naturally subject to risks and
contingencies that may lead to actual results materially differing from those explicitly or implicitly included in these statements. The Company does not undertake to update or revise the forward-looking statements that may be presented in this document to reflect new information, future events or for any other reason and any opinion expressed in this presentation is subject to change without notice.
No representation or warranty, express or implied, is made as to, and no reliance should be placed upon, the fairness, accuracy, completeness or correctness of the Information and none of the Company, the Banks, their affiliates, shareholders, directors, advisors, employees and representatives accept any responsibility in this respect.
The Information does not constitute a recommendation regarding the Proposed Transaction and does not purport to contain all information that may be required to evaluate the Proposed Transaction. The merit and suitability of an investment in the Company should be independently
evaluated and any person considering such an investment in the Company is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other related advice prior to making an investment. Investors should not subscribe for or purchase any securities of the Company except on the basis of information in a final form prospectus that may be published by the Company, which would supersede this presentation in its entirety and would contain a description of risk factors pertaining to the Company, its businesses and such an investment. In accepting the Information the recipient acknowledges that it makes all trading and investment decisions in reliance on its own judgment and not in reliance on any of the Company, the Banks, their affiliates, shareholders, directors, officers, advisers, employees or representatives.
The Banks are acting solely for the Company in connection with the Proposed Transaction and no one else. They will not regard any other person (whether or not a recipient of the Information) as a client in relation to the Proposed Transaction and, accordingly, will not be responsible to any other person for providing the protections afforded to their respective clients, or for advising any such person in relation to the contents of the Information or in connection with the Proposed Transaction.
The Information does not constitute or form part of a prospectus or any offer or invitation for the sale or issue of, or any offer or inducement to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for any shares or other securities in the Company in France, the United Kingdom, the United States or any other jurisdiction. It does not constitute any form of commitment on the part of the Company or any other person. Neither the Information nor any other written or oral information made available to any recipient or its advisers will form the basis of any contract or commitment whatsoever. In particular, in furnishing the Information, the Company, the Banks, their affiliates, shareholders, directors, officers, advisers employees or representatives undertake no obligation to provide the recipient with access to any additional information. In the European Economic Area ("EEA") the Information is only addressed to and directed at persons in member states who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) ("Qualified Investors").
Within the United Kingdom, the Information is intended for distribution only to persons who are Qualified Investors who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order
2005, as amended (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order or (iii) are persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons") and in such a case any investment or investment activity to which the Information relates is available only to relevant persons and will be engaged in only with relevant persons.
Securities may not be offered, subscribed or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements thereof. The securities of the Company have not been and will not be registered under the U.S. Securities Act and the Company does not intend to make a public offer of its securities in the United States. Neither this document nor any copy of it may be taken or transmitted into, directly or indirectly, into the United States, other than to "qualified institutional buyers", within the meaning of Rule 144A under the Securities Act.
Neither this document nor any copy of it may be taken or transmitted into Australia, Canada or Japan or to any person in any of those jurisdictions.
P2 •
INVESTMENT HIGHLIGHTS
- Most advanced product in clinical phase 3
- Tier 1 partnerships > Teva Pharmaceuticals and the Bill & Melinda Gates Foundation
- Products based on approved APIs and 505(b)2
- Polymerjoint-venture with Corbion (Amsterdam: CRBN)> GMP polymers available at commercial scale
© MedinCell - January 2020
PORTFOLIO
(as of January 1st, 2020)
IND / IMPD
Approval for Human Clinical Trials
mdc-TJK | mdc-CWM | mdc-IRM | |||
Next potential candidates for preclinical & IND/IMPD | Antipsychotic | Pain & inflammation (opioid free) | Schizophrenia | ||
> 7 products in formulation and preclinical | Subcutaneous injection | Intraarticular injection | Subcutaneous injection | ||
Partner: Teva pharmaceuticals | Partner: Arthritis Innovation Corporation | Partner: Teva pharmaceuticals | |||
Formulation | Preclinical | Clinical phase 1 | Clinical phase 2 | Clinical phase 3 | NDA / Market |
P3 •
LAST 12-MONTH NEWSFLOW & CASH POSITION
Press releases are available on invest.medincell.com
Clinical newsflow | FDA IND clearance to initiate | mdc-CWM | Start of first in human | ||||||||
clinical activities of mdc-TJK | progresses as planned | for mdc-TJK | |||||||||
2019 | |||||||||||
January | February | March | April | May | June | July | August | September | October | November | December |
In vivo demonstration of the efficacy of the first injectable combining surgical anesthesia and 3 days opioid free postoperative pain management
Funding from the Gates Foundation for the second formulation phase of a 6-month injectable contraceptive
7,5 M€ | New grant from | |
from the | the Gates Foundation for | |
European | feasibility study for HIV PrEP | |
Investment Bank | ||
mdc-ANG enters | New US partner to address | Additional $19 M grant |
preclinical development | untapped financial potential | from the Bill & Melinda Gates |
in Animal Health | Foundation for mdc-WWM |
MedinCell - January 2020
Cash position
as of September 30, 2019
- 16,1 M€ in cash and cash equivalents
- 0,7 M€ inshort-term investments
- 3,9 M€ innon-current financial assets
- 5 M€ drawable from the European Investment Bank loan under conditions
©
Note: $4.9 million upfront out of $19 million received in November 2019 from the Gates Foundation
P4 •
CLINICAL UPCOMING DEVELOPMENT NEWSFLOW
As programs based on MedinCell's technology move into more advanced phases, data, analysis and conclusions may only be communicated on an ad hoc basis to preserve clinical study integrity and competitive positioning
Program
Current status
Next potential milestone
mdc-IRM
Partner: Teva pharmaceuticals
Phase 3
-
multicenter, randomized,double-blind,placebo-controlled study to evaluate the efficacy, safety, and tolerability of risperidone
extended-release injectable suspension for subcutaneous use as maintenance treatment in adult and adolescent patients with schizophrenia
Location: United States
Start date: April 2018
Estimated enrollment: 596 participants
Primary endpoint : Time to impending relapse
Estimated completion date: H2 2020
> US Phase 3 interim analysis >H2 2020
Program
Current status
Next potential milestone
mdc-CWM
Partner: Arthritis Innovation Corporation
Phase 2
- Phase 2, randomized,single-blind,active-control, parallel group study to evaluate safety and activity of a single administration of celecoxib for management of postoperative pain in participants undergoing unilateral total knee replacement (TKR)
Location: United States
Start date: May 2018
Enrollment: 20 participants
Primary endpoints : pain measures and post- surgical opioid consumption
Primary completion date: Summer 2020
> US Phase 2 completion >H1 2020
© MedinCell - January 2020
Program | Current status | Next potential milestone | |
Phase 1 | Location: United States | ||
mdc-TJK | |||
Start date: Q4 2019 | > US Phase 1 results > 2021 | ||
Partner: Teva pharmaceuticals | Safety study | ||
Primary endpoints : Safety | |||
P5 •
© MedinCell - January 2020
NEXT POTENTIAL CANDIDATES FOR PRECLINICAL & IND
- 7 PRODUCTS IN FORMULATION AND PRECLINICAL
- SUBCUTANEOUS INJECTION
PROGRAM | PARTNER / INTERNAL | CURRENT STATUS | INDICATION | MOLECULE | MAIN TARGETED IMPACT |
mdc-ANG | Partner: | Preclinical | Antipsychotic | confidential | Adherence |
Teva Pharmaceuticals | |||||
mdc-GRT | MedinCell program | Formulation | Organ transplant | Tacrolimus | Adherence |
mdc-WWM | Partner: | Formulation | Women's contraception | Progestin molecule | Large access to best-in-class |
the Bill & Melinda Gates Foundation | (non-MPA) | women's contraceptive | |||
mdc-KPT | Partner: | Formulation | Pain | Confidential | Duration |
(Animal Health) | Cornerstone Animal Health |
Animal Health offers an attractive risk profile as the products can be tested in the target species during the lead formulation selection. Development times are significantly shorter and funding requirements may be one order of magnitude lower compared to human health products.
mdc-STG | MedinCell program | Formulation | Confidential | Confidential | Confidential |
> PERINEURAL INJECTION
PROGRAM | PARTNER / INTERNAL | CURRENT STATUS | INDICATION | MOLECULE | MAIN TARGETED IMPACT |
mdc-CMV | MedinCell program | Preclinical | Anesthesia & pain | Ropivacain | Opioid free |
(opioid free) | |||||
mdc-NVA | MedinCell program | Formulation | Chronic pain | Ropivacain | Opioid free |
(opioid free) |
P6 •
BEPO®: LAI CUTTING EDGE POLYMER TECHNOLOGY
© MedinCell - January 2020
Formulation | Subcutaneous | Controlled release | |
or local injection | |||
Polymers customized formulation for each | In situ depot precipitates immediately | API is released as depot fully degrades | |
indication | after subcutaneous or local injection | ||
• | PEG/PLA | ||
• | Hydrophilic solvent | ||
• | Active pharmaceuticals Ingredient |
P7 •
WE APPLY OUR LAI TECHNOLOGY BEPO®TO MAKE DRUGS EFFICIENT
© MedinCell - January 2020
DRUG LEVEL
Time impact
- known approved API
- same indication
TOXICITY LEVEL
LAI
Controlled and customized release for days, weeks or months
THERAPEUTIC LEVEL
TIME
Space impact
> known approved API > new indication
P8 •
WE APPLY OUR LAI TECHNOLOGY BEPO®TO ALREADY KNOWN APPROVED APIs
Attractive risk / return profile
Simpler regulatory pathways e.g. US 505(b)(2) Significantly less financial resources needed
Significantly less risk in clinical phases especially when same original indication
HIGH
NCE | LAIs |
(New Chemical Entity) | with approved APIs |
RETURN
GENERIC
LOW
LOW | HIGH |
SUCCESS RATE
© MedinCell - January 2020
P9 •
Portfolio
3 products in clinical trials
© MedinCell - January 2020
IND / IMPD
Approval for Human Clinical Trials
mdc-TJK | mdc-CWM | mdc-IRM | |||
Antipsychotic | Pain & inflammation (opioid free) | Schizophrenia | |||
Subcutaneous injection | Intraarticular injection | Subcutaneous injection | |||
Partner: Teva pharmaceuticals | Partner: Arthritis Innovation Corporation | Partner: Teva pharmaceuticals | |||
Formulation | Preclinical | Clinical phase 1 | Clinical phase 2 | Clinical phase 3 | NDA / Market |
P10 • |
Portfolio
3 products in clinical development
mdc-IRM
SUBCUTANEOUS RISPERIDONE
First long-acting injectable antipsychotic with Teva Pharmaceuticals
Maintenance treatment of schizophrenia
Current status: US Phase 3 (efficacy, safety and tolerability) - Initiated Q2 2018 - 596 patients
All development costs covered by Teva Pharmaceutical
IND / IMPD | |||||
Approval for Human Clinical Trials | |||||
mdc-IRM | |||||
Schizophrenia | |||||
2020 | Subcutaneous injection | ||||
Completed | Exempted | Partner: Teva pharmaceuticals | |||
5O5(b)2 | |||||
-January | |||||
Preclinical | Clinical phase 1 | Clinical phase 2 | Clinical phase 3 | NDA / Market | |
Formulation | |||||
© MedinCell | P11 • |
© MedinCell - January 2020
Portfolio
3 products in clinical development
mdc-IRM
SUBCUTANEOUS RISPERIDONE
> SCHIZOPHRENIA: A CHRONIC PSYCHOSIS AFFECTING 1% OF POPULATION WW
An extremely debilitating | Positive symptoms: hallucinations, disorganized speech, delusions |
disease | Negative symptoms: flat affect, poverty of speech |
Cognitive symptoms: attention, memory, executive functions | |
Nonadherence to | 74% of patientshad discontinued medication within 18 months due to insufficient efficacy, intolerable side |
prescribed treatments | effects or for other reasons(Lieberman J. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223) |
Schizophrenia in the US | Schizophrenia accounts for 20% of all hospital bed-daysand over 50% of all psychiatric beds1 |
Annual cost:between $134 and $174 billion per year2 | |
$38 billion for excess direct health care costs | |
Hospital inpatient treatment, outpatient and emergency department visits, medications | |
$9 billion for direct non-health care costs | |
Law enforcement, incarceration, homeless shelters | |
$117 billion for indirect costs | |
Unemployment, lost productivity, premature mortality | |
Sources: 1Comprehensive understanding of schizophrenia and its treatment, Maguire GA. Am J Health Syst Pharm. 2002 ; 2Analysis Group, Otsuka, Lundbeck LLC - 2016 | |
P12 • |
Portfolio
3 products in clinical development
mdc-IRM
SUBCUTANEOUS RISPERIDONE
> ATYPICAL ANTIPSYCHOTICS LAIs: A $5.2 BILLION MARKET GROWING +20% CAGR (7 Major Markets)
Global atypical antipsychotics sales | LAI atypical antipsychotics sales | Global atypical | |||||||||||||||||||||||||||
$ billion - 7 MM - 2018 | $ billion - 7MM - 2018 | antipsychotics patients | |||||||||||||||||||||||||||
17,4 | 5.2 | 7MM - 2016 | |||||||||||||||||||||||||||
15,9 | 15,4 | 16,2 | |||||||||||||||||||||||||||
13,3 | 13,5 | 4.3 | Japan | ||||||||||||||||||||||||||
12,6 | |||||||||||||||||||||||||||||
3.6 | EU | 11% | |||||||||||||||||||||||||||
2.9 | |||||||||||||||||||||||||||||
2.6 | |||||||||||||||||||||||||||||
2.2 | |||||||||||||||||||||||||||||
1.7 | |||||||||||||||||||||||||||||
US | |||||||||||||||||||||||||||||
5,2 | |||||||||||||||||||||||||||||
4,3 | |||||||||||||||||||||||||||||
3,6 | |||||||||||||||||||||||||||||
2,6 | 2,9 | 89% | |||||||||||||||||||||||||||
2,2 | |||||||||||||||||||||||||||||
1,7 | |||||||||||||||||||||||||||||
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | ||||||||||||||||
LAI | Oral | Total | US | EU5 | JAPAN | ||||||||||||||||||||||||
Oral LAI
© MedinCell - January 2020
5-year LAIs CAGR
20%
Source: IMS Sales date, Midas & Globaldata
USAis largest market:
77%of sales
Fastest Growth (+25% CAGR)
LAIsaccount for only
11% of patients
P13 •
Portfolio
3 products in clinical development
mdc-TJK
SUBCUTANEOUS ANTIPSYCHOTIC
Second long-acting injectable antipsychotic with Teva Pharmaceuticals API: confidential
Current status: US Phase 1 (safety) - Initiated Q4 2019 All development costs covered by Teva Pharmaceuticals
© MedinCell - January 2020
IND / IMPD
Approval for Human Clinical Trials
mdc-TJK
Antipsychotic
Subcutaneous injection
Partner: Teva pharmaceuticals
Formulation | Preclinical | Clinical phase 1 | Clinical phase 2 | Clinical phase 3 | NDA / Market |
P14 •
TEVA COLLABORATION
> 3 ANTIPSYCHOTICS
All development costs covered by TEVA
MedinCell receives
- FTE remuneration in formulation
- Development and commercial milestones of up to $122m for each product ($366m total)
- Royalties on sales
Press release - Dec. 3, 2019
Teva update on the three antipsychotic products
Clinical activities begin for Second Long-acting Injectable Antipsychotic mdc-TJK. The first-inhuman study for the investigational long-acting injectable antipsychotic mdc-TJK has now commenced. The results of this study, expected during 2021, will inform future development. mdc-TJK is one of three antipsychotic products in development by the partner Teva Pharmaceuticals based on MedinCell's technology.
The phase 3 clinical trials for the lead asset, mdc-IRM, are ongoing with an interim analysis in the second half of 2020 contingent upon the projected recruitment rate and patient relapse events.
Non-clinical work on the third investigational product, mdc-ANG, continues to progress and will inform a decision on further development expected in the second half of 2020.
FTE remuneration | Development milestones | Commercial milestones | ||||
& royalties | ||||||
IND / IMPD | ||||||
Approval for Human Clinical Trials | ||||||
mdc-TJK | mdc-IRM | |||||
Antipsychotic | Schizophrenia | |||||
2020 | Subcutaneous injection | Subcutaneous injection | Subcutaneous injection | |||
Partner: Teva pharmaceuticals | Partner: Teva pharmaceuticals | |||||
• | mdc-ANG | |||||
-January | (Partner: Teva pharmaceuticals) | |||||
Preclinical | Clinical phase 1 | Clinical phase 2 | Clinical phase 3 | NDA / Market | ||
Formulation | ||||||
© MedinCell | P15 • |
Portfolio
3 products in clinical development
mdc-CWM
INTRA-ARTICULAR CELECOXIB INJECTION
Collaboration with AIC
Total Knee Replacement (TKR) post-operative pain and inflammation treatment
Current status: US Phase 2 (safety and activity) - Initiated Q4 2019 Clinical development cost borne by AIC
IND / IMPD
Press release - September 20, 2019
MedinCell announces that mdc-CWMprogresses as planned
MedinCell's CEO Christophe Douat states: "We are happy to report that the mdc-CWM program, partnered and in phase 2 clinical trial, is progressing well and on schedule."
As a reminder, recruitment was capped by MedinCell's partner at 20 patients for the active phase 2 clinical study in April 2019. All participants have completed their 3-monthfollow-up visit this summer. The analysis of the data is being completed by our partner and its subcontracted clinical research organization. 12-month trial completion is scheduled on March 2020. Our partner plans to meet with FDA in the meantime to discuss the current findings and how to progress in the next trial moving forward.
The product is for management of postoperative pain in participants undergoing unilateral total knee replacement. The study's primary endpoints include pain measures and post-surgical opioid consumption.
MedinCell's CEO Christophe Douat adds: "While total knee replacement surgery leads to decreased pain in most patients, a sizable minority continue to experience severe pain and consume opioids chronically after it. It is one of the surgeries were patients use the most opioids and an estimated 15 % of these, or 150 000 patients per year, become new persistent opioid users for many months after surgery. A decrease in pain and opioid consumption should be viewed as a very positive factor in the current opioid crisis, which is one of the highest priorities of the FDA."
© MedinCell - January 2020
Approval for Human Clinical Trials
mdc-CWM | |||||
Antipsychotic | |||||
Subcutaneous injection | |||||
Exempted | Partner: Teva pharmaceuticals | ||||
5O5(b)2 | |||||
Formulation | Preclinical | Clinical phase 1 | Clinical phase 2 | Clinical phase 3 | NDA / Market |
P16 •
Portfolio
3 products in clinical development
1.5M | ||
mdc-CWM | 0.7M | |
2010 | 2030forecast | |
INTRA-ARTICULAR CELECOXIB INJECTION | ||
NUMBER OF TKR PROCEDURES IN THE US
Source: GlobalData, Orthopedic Devices [Knee Reconstruction] Market, United States, 2009-2023, Absolute Units, 2017
> A STRONG MARKET OPPORTUNITY
Unsatisfying
post-surgery pain treatment
Significant pain for two weeks and reduced but continued pain for 6-12 weeks post surgery Contraindication of traditional oral anti-inflammatory products post surgery
Effectiveness of current practices for postoperative pain management remains limited: 57% to 73% of operated patients report moderate to extreme postoperative pain, leading to longer hospitalization stay, revision surgery,
disability leave, etc.
Source: Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: Results from a US national survey. Curr Med Res Opin. 2014;30(1):149-160
© MedinCell - January 2020
Opioids epidemic issue | 15.2% of TKR patients become long-term opioid users |
Source: 2018 Choices Matter Survey - Exposing a silent gateway to persistent opioid use | |
The use of opioids in the treatment of postoperative pain is globally widespread and particularly in the US: c. 90% | |
of operated patients | |
Negative side effects observed in 96% of operated patients, increasing the duration of hospitalization in 55% of | |
cases | |
130 people die every day in the US because of opioids overdose according to the CDC | |
Sources: Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: Results from a US national survey. Curr Med Res Opin. 2014;30(1):149-160 ; sler ER, Shah M, | |
Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: Opioid-related adverse events and their impact on clinical and economic | |
outcomes. Pharmacotherapy. 2013;33 | |
P17 • |
© MedinCell - January 2020
Portfolio
3 products in clinical development
mdc-CWM
INTRA-ARTICULAR CELECOXIB INJECTION
> PRODUCT DETAILS
Molecule | Celecoxib, approved by the FDA in the pain treatment in 1998 often |
used in the treatment of acute pain, rheumatoid arthritis, ankylosing | |
spondylitis etc. | |
Duration | Up to three months |
Mechanism of | One-time local delivery for the control of post-total knee replacement |
action | pain and inflammation through sustained release of Celecoxib in the |
intraarticular space, with improved safety (better cardio and | |
gastrointestinal-toxicity profiles) | |
Little to no systemic exposure avoids risk of adverse NSAID issues | |
Partner | AIC (Arthritis Innovation Corporation): |
-
deal metricsCompany founded by North American physicians & entrepreneurs All development costs borne by AIC
50-50 profit sharing
PGE2 concentration in the synovial fluid with and without mdc-CWM
2 500 | Control | |||
2 000 | ||||
(pg/ml) | mdc-CWM | |||
1 500 | ||||
PGE2 | 1 000 | |||
500 | ||||
0 | ||||
0 | 30 | 60 | 90 |
Time (days)
Data represents means, Day 0, n=35, Day 7, n=5, 4 for F14, Control; Day 30 & 90, n=5
Pre-clinical in vivo tests demonstrated efficacy, reducing PGE2 concentration for up to 3 months
P18 •
Collaboration with the
Bill & Melinda Gates Foundation
Collaboration with the Bill & Melinda Gates Foundation
© MedinCell - January 2020
> ADDRESSING MAJOR CHALLENGES OF FAMILY PLANNING WORLDWIDE
Press release - November 28, 2019
MedinCell receives $19 million grant for its mdc-WWM program
French company MedinCell and the Bill & Melinda Gates Foundation have signed an agreement for up to an additional $19 million to be granted over four years. It aims to fund preclinical activities and a phase 1 clinical trial for the injectable six-month bioresorbable contraceptive (mdc-WWM). The grant is structured in advanced installments to cover the costs that will be incurred by the project. Depending on the options chosen and on the advancement of the program, up to $11.75 million could be raised over the next 12 months including a first tranche of $4.75 million to be paid immediately. The additional $7.25 million may be collected later.
As a reminder, a previous grant of $3.5 million was awarded in November 2017 by the Gates Foundation to fund the formulation research phase. Full results should make it possible to select the candidate formulation.
MedinCell owns all marketing rights of the product worldwide, including the United States where the contraceptive market totaled more than $5 billion in 2018. Long-acting reversible contraceptives (LARC) alone (primarily solid implants and intrauterine devices) represented 28% of this market - more than $1.4 billion - with a 5-year CAGR at 7.8%. The mdc-WWM product could capture a significant share of this LARC market and even expand it easing the adoption of this type of contraception1.
In accordance with the Global Access strategy of both partners and to ensure a significant impact on women's lives, the objective is to make the product widely available. Affordable pricing in emerging economies will help eliminate cost as a barrier to increased availability and voluntary access to the product. High demand among women and girls for long-acting contraceptive options illustrate the potential for market growth and measurably improving maternal, newborn and child health. The Gates Foundation also has a non-exclusive license for non-commercial market in low- and middle-income countries.
> EXPLORATORY WORK IN HIV PrEP
Press release - November 28, 2019
MedinCell receives $19 million grant for its mdc-WWM program
Pre-exposure prophylaxis (PrEP) strategy has proven efficacy in preventing HIV infection via daily oral administration of antiretroviral drugs. However, lack of adherence to an oral PrEP regime undermines its effectiveness. A combination of an investigational PrEP single-agent with MedinCell's long-acting injectable technology could guarantee several months of prevention after a single subcutaneous injection. The support of the Bill & Melinda Gates Foundation aims to confirm the feasibility of the product and to initiate the design of a lead formulation that could rapidly enter investigational development.
P20 •
Collaboration with the Bill & Melinda Gates Foundation
> mdc-WWM:6-MONTH SUBCUTANEOUS CONTRACEPTIVE
December 2017
$3.5 million grant
to fund the formulation of the product
November 2019
Up to $19 million additional grant
over four years to fund preclinical activities and phase 1 clinical trial. The grant is structured in advanced installments to cover the costs that will be incurred by the project
The challenge of familyAn estimated74 million women fall pregnant unintentionally every year leading to25 million unsafe abortions
planning worldwideand47,000 maternal deaths (WHO - Oct. 2019)
Best-in-classproductmdc-WWM could be the first contraceptive to combine the following essential features to make it a best-in-class product worldwide: progestin molecule (non-MPA),6-month duration, subcutaneous injection, full bio resorption, affordability
> MEDINCELL OWNS THE COMMERCIAL RIGHTS WORLDWIDE, ESP. IN THE US
US contraceptive market | > $5 billion |
in 2018 |
© MedinCell - January 2020
Long-acting reversible | > 28% of the US market |
contraceptives - LARC | > $1.4 billion |
(primarily solid implants and | |
> 5-year CAGR at 7.8% | |
intrauterine devices) |
mdc-WWM product could capture a significant share of this LARC market and expand it by easing the adoption of this type of contraception
Source: IQVIA
P21 •
Impact company
© MedinCell - January 2020
WE CONTRIBUTE TO SOLVING GLOBAL HEALTH CHALLENGES
- Compliance & access are key issues in developing world
-
WHO estimates thatone patient in two does not start or does not continue to follow their treatment and thatadherence improvement would have a greater impact than any improvement in specific
medical treatments(World Health Organization: Adherence to Long-Term Therapies, Evidence for Actions - 2003) - LAI can impact both compliance and access issues
-
WHO estimates thatone patient in two does not start or does not continue to follow their treatment and thatadherence improvement would have a greater impact than any improvement in specific
- Affordability should allow to tap profitability reservoir on developing countries
- Much higher volumes will counter balance pricing
- Low COGS technology
- Pharmaceutical residues becoming a major environmental challenge
- Up to 95% less APIs required for a same treatment
- 1/3 of US presription become waste
(MedinCell estimates on potential positive impact of BEPO)
P23 •
© MedinCell - January 2020
A XXIstCENTURY PHARMA COMPANY MODEL
"Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives."
"Raison d'etre"̂of MedinCell voted by the General Assembly in September 2019
- 25 nationalities out of 130 employees
- 100% of MedinCell employees are shareholders or soon to be
Employee share ownership is promoted through adapted tools that guarantee alignment of the interests of employees and other shareholders. It enables a fair sharing of the value created and a balanced relationship between management and all employees
- Reduced salary gaps
- Collective bonus linked to product progress
P24 •
KEY FINANCIALS
€ million | 6-Month period | 6-Month period | |
September 30, 2019 | September 30, 2018 | ||
Revenue | 3.9 | 1.8 | |
Operating result | (8.1) | (6.6) | |
Net result | (9.0) | (9.8) | |
Earning per share (€) | (0.45) | (0.68) | |
Cash position | 16.1* | 11.4** | |
* not including 0.7 M€ in short-term investments, 3.9 M€ in non-current financial | |||
assets and 5 M€ drawable under conditions from the European Investment Bank loan | |||
2020 | ** not including 4.6 M€ in short-term investments and non-current financial assets | ||
© MedinCell - January |
Employees, Consultants | Nguyen Family* |
and Affiliates | |
16% | 21% |
Former employees
and Affiliates
30%
Other
33%
*Anh Nguyen, Chairman of MedinCell
Market Cap: c. 140 M€
outstanding shares: 20.1 M
ISIN: FR0004065605
P26 •
Attachments
- Original document
- Permalink
Disclaimer
Medincell SA published this content on 14 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 January 2020 11:42:01 UTC